CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病例报告：CAR-T 联合 ASCT 的夹心治疗：CAR-T 治疗缓解后序贯 CAR-T 细胞治疗联合 ASCT 使一例伴 TP53 突变的复发/难治性伯基特淋巴瘤患者获得长期生存
英文原题：Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.
查看英文原题
Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
伴TP53突变的伯基特淋巴瘤（BL）患者接受标准免疫化疗后常预后不佳。过继CAR-T 可能为复发/难治性BL提供新治疗方式，但疗效仍未确定。本文报告一例复发/难治性BL患者，多方案化疗后未达完全缓解且迅速进展。患者接受CAR19和CAR22 T细胞联合治疗后达到完全缓解，随后进行自体造血干细胞移植，并再次接受CAR19/CAR22联合治疗，获得长期无病生存期。该病例的临床过程和遗传特征可能为克服TP53突变相关复发的CAR-T 治疗提供参考。
展开英文摘要原文
Burkitt's lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive.
Here, we report a patient with r/r BL who failed to achieve complete remission (CR) and progressed rapidly after multiple protocol chemotherapy. The patient achieved CR with CAR19 and CAR22 T-cell cocktail therapy and obtained long-term disease-free survival after autologous hematopoietic stem cells (ASCT) and subsequential CAR19 and CAR22 T-cell cocktail therapy. The clinical evolution and genetic features of this case may provide some guidance for CAR-T therapy in overcoming relapses associated with TP53 gene mutations.
论文信息
- 作者
- Zhang Q、Zhu X、Liu B、Zhang Y、Xiao Y
- 单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.China
- 文献类型
- 病例报告 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 37006273 · DOI 10.3389/fimmu.2023.1127868
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →